NCT03590392View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Chikungunya Fever
Interventions
BIOLOGICAL

ChAdOx1 Chik

ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.

Trial Locations (1)

Unknown

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03590392 - Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001) | Biotech Hunter | Biotech Hunter